
CLAIMS

1. A pharmaceutical composition for use in the treatment of chronic kidney disease in a human, comprising Compound I :



and one or more pharmaceutically acceptable carriers, wherein the pharmaceutical composition is in an oral dosage form formulated for a daily dose of 0.1 to 1.0 mg.

2. The pharmaceutical composition for use according to claim 1, wherein the daily dose is from 0.1 to 0.5 mg.

3. The pharmaceutical composition for use according to claim 2, wherein the daily dose is from 0.2 to 0.5 mg.

4. The pharmaceutical composition for use according to claim 1, wherein administration of the composition to a human results in a bioavailability of Compound I of 50% or more.

5. The pharmaceutical composition for use according to claim 4, wherein a D_{90} of Compound I is 25 μm or less.

6. The pharmaceutical composition for use according to claim 5, wherein the D_{90} of Compound I is 10 μm or less.

7. The pharmaceutical composition for use according to claim 4 wherein the pharmaceutical composition comprises one or more surfactants selected from the group consisting of benzalkonium chloride, sodium lauryl sulfonate, sodium dodecyl sulfate, glycerol, cholic acid, poloxamer, polyvinyl alcohol, Polysorbate 80, PVP K_{30} and polyethylene glycol.

8. The pharmaceutical composition for use according to claim 7, wherein the pharmaceutical composition comprises one or more surfactants selected from the group consisting of benzalkonium chloride, sodium lauryl sulfonate, and sodium dodecyl sulfate.

9. The pharmaceutical composition for use according to claim 8, wherein the pharmaceutical composition comprises one surfactant selected from the group consisting of benzalkonium chloride, sodium lauryl sulfonate, and sodium dodecyl sulfate.

10. The pharmaceutical composition for use according to claim 7, wherein the weight ratio of Compound I to the surfactant is between 1:0.1 to 1:20.

11. The pharmaceutical composition for use according to claim 10, wherein the weight ratio is between 1:1 to 1:20.

12. The pharmaceutical composition for use according to claim 1, wherein the pharmaceutical composition is a tablet, a sustained release tablet, a capsule, a granule, a soft capsule, a dripping pill, a micro-capsule, a micro-sphere, a liposome, a self-emulsifying drug delivery system, a solid dispersion, a micelle, an oral melt tablet, a solution, a suspension, or an emulsion.

13. The pharmaceutical composition for use according to claim 1, wherein when oral administration to a patient having chronic kidney disease in need thereof, results in a safe and effective area under plasma concentration-time curve (AUC) of from 188 ng*h/mL to 3173 ng*h/mL.

14. The pharmaceutical composition for use according to claim 13, wherein the AUC ranges from 188 ng*h/mL to 2893 ng*h/mL.

15. The pharmaceutical composition for use according to claim 14, wherein the AUC ranges from 188 ng*h/mL to 2613 ng*h/mL.

16. The pharmaceutical composition for use according to claim 15, wherein the AUC ranges from 188 ng*h/mL to 1117 ng*h/mL.

17. The pharmaceutical composition for use according to claim 16, wherein the AUC ranges from 188 ng*h/mL to 885 ng*h/mL.

18. The pharmaceutical composition for use according to claim 1, in the form of a single dose of 0.1 to 1.0 mg.

19. The pharmaceutical composition for use according to claim 1, in the form of a single dose of 0.1 to 0.5 mg.

20. The pharmaceutical composition for use according to claim 1, in the form of a single dose of 0.2 to 0.5 mg.

21. Use of the pharmaceutical composition according to any one of claims 1 to 17 in the preparation of a medicament for treating and/or preventing chronic kidney disease.